PureTech's Akili raises $30.5M for ADHD-treating video game; Amgen wins expanded Kyprolis nod;

@FierceBiotech: Sanofi's reportedly on the verge of 'sizable' job cuts as diabetes business sputters. Story | Follow @FierceBiotech

@JohnCFierce: You've got to have a code for Twitter: Rule #1. If you want to poke at me, fine. But if you're anonymous, you get blocked. #comeoutandplay. | Follow @JohnCFierce

@DamianFierce: The $SRPT cancellation robbed us of a situation in which Ed Kaye and Janet Woodcock are trapped in White Oak and have to unite to survive. | Follow @DamianFierce

> PureTech Health's Akili Interactive, developing a video game to treat ADHD, raised $30.5 million to push its lead product toward a 2017 launch. More

> More and more Chinese entrepreneurs are embracing the country's nascent biotech scene, hoping to develop blockbuster therapies and compete with the world's top drugmakers. News

> Amgen's ($AMGN) blood cancer therapy Kyprolis won an expanded FDA approval. Item

Medical Device News

@FierceMedDev: Video game neuro therapy company Akili Interactive raises $30M+. More | Follow @FierceMedDev

@EmilyWFierce: Shkreli's 5th Amendment hall pass rejected for congressional drug pricing hearing. Story | Follow @EmilyWFierce

> Mayo Clinic dispatches UV-emitting robots to fight drug-resistant bacteria. More

> St. Jude recalling some defibrillator leads due to poor insulation. Story

Pharma News

@FiercePharma: Veterinarian turns dog owner's tragedy into cloud-based EHR for pets. More | Follow @FiercePharma

@EricPFierce: #EMA suspends Hubei Hongyuan Pharmaceutical after Czech inspectors find dust-covered plant and equipment. Story | Follow @EricPFierce

@CarlyHFierce: Glaxo CEO: Consumer health can stand on its own, but don't expect a quick spinoff. Article | Follow @CarlyHFierce

> Yes, Gilead put superhigh prices on hep C drugs, but what can you do? Senators ask. More

> Amgen's Kyprolis wins 'backbone therapy' FDA nod after trumping Velcade in trial. Story

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.